Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2015Inflammatory Bowel DiseasesOpen Access

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEdward SheltonRoyal Veterinary CollegeJAJessica R. AllegrettiBrigham and Women's HospitalBSBetsy W. StevensHarvard University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shelton et al. (2015) studied this question.

synapsesocial.com/papers/69db2bcd5b363cdf1c835873https://doi.org/10.1097/mib.0000000000000561
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term outcome after infliximab for refractory ulcerative colitis2008 · 224 citations
  2. 2Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry2012 · 805 citations
  3. 3Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohnʼs Disease2013 · 22 citations
  4. 4Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed2014 · 718 citations